918972-54-0 Usage
Description
Montelukast Styrene, also known as Montelukast EP Impurity B, Montelukast USP Related Compound F, Montelukast Methylstyrene, or Styrene Montelukast, is a pale yellow solid that is an impurity found in Montelukast, a medication used for treating asthma and allergic rhinitis. It is a chemical byproduct that can affect the purity and quality of the final Montelukast product.
Uses
Montelukast Styrene is primarily used as a reference standard for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity and safety of Montelukast medications by providing a benchmark for comparison during testing and analysis.
Used in Pharmaceutical Industry:
Montelukast Styrene is used as a reference standard for quality control and analytical testing to ensure the purity and safety of Montelukast medications. It serves as a benchmark for comparison during testing and analysis, helping to maintain the quality and efficacy of asthma and allergic rhinitis treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 918972-54-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,8,9,7 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 918972-54:
(8*9)+(7*1)+(6*8)+(5*9)+(4*7)+(3*2)+(2*5)+(1*4)=220
220 % 10 = 0
So 918972-54-0 is a valid CAS Registry Number.
InChI:InChI=1/C35H34ClNO2S/c1-24(2)31-9-4-3-7-26(31)13-17-33(40-23-35(18-19-35)22-34(38)39)28-8-5-6-25(20-28)10-15-30-16-12-27-11-14-29(36)21-32(27)37-30/h3-12,14-16,20-21,33H,1,13,17-19,22-23H2,2H3,(H,38,39)/b15-10+/t33-/m1/s1
918972-54-0Relevant articles and documents
Identification, synthesis and characterization of impurities of Montelukast sodium
Sunil Kumar,Anjaneyulu,Hima Bindu
, p. 4536 - 4546 (2012/02/04)
Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.
PROCESS FOR PREPARING MONTELUKAST SODIUM CONTAINING CONTROLLED LEVELS OF IMPURITIES
-
Page/Page column 9, (2008/12/07)
The present invention is directed to a process of preparing montelukast or a salt thereof with minimal amounts of impurities, such as a dehydration impurity (compound (VI)) or a cyclic ether impurity (compound (VIII)).
PREPARATION OF MONTELUKAST
-
Page/Page column 26, (2008/06/13)
A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying.